Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: SERPINB6 is upregulated in glioma tissues and cell lines and predicts poor prognosis. (A) TCGA database analysis shows the SERPINB6 expression levels in 33 types of cancer tissues and their corresponding normal tissues. ** p < 0.01, *** p < 0.001, Wilcoxon rank sum test. (B) TCGA database analysis shows the SERPINB6 expression levels in glioma tissues and their corresponding normal tissues. *** p < 0.001, Wilcoxon rank sum test. (C–F) SERPINB6 expression in different grades of glioma in TCGA, CGGA_693 and CGGA_693 datasets, respectively. * p < 0.05, ** p < 0.01, **** p < 0.0001, one‐way ANOVA; **** p < 0.0001, Student's t ‐test. (G) qRT‐PCR analysis of SERPINB6 expression in human glioma samples and normal brain tissues. ** p < 0.01, Student's t ‐test. (H) Immunoblot analysis of SERPINB6 expression in human glioma samples and normal brain tissues. GAPDH was used as loading control. (I) Immunoblot analysis of SERPINB6 expression in human glioma cell lines (U87, SNB19, A172 and U251) and Normal Human Astrocytes (NHAs). GAPDH was used as loading control.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: SERPINB6 shows a high prognostic prediction value in glioma patients. The Kaplan–Meier plotter database analysis shows the differences in (A) overall survival, (B) disease‐specific survival and (C) progression‐free interval of glioma patients with high‐ and low‐SERPINB6 expression levels. *** p < 0.001, Log‐rank test. (D) Diagnostic ROC curves to distinguish glioma tissues and normal tissues based on the SERPINB6 expression levels. (E) Time‐dependent survival ROC curves to predict 1‐, 3‐ and 5‐year survival rates of glioma patients based on the SERPINB6 expression levels.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Expressing, Diagnostic Assay

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: Analysis of the correlation between SERPINB6 expression and immune cell infiltration. (A) Correlation between various immune cell infiltrations in glioma tissues and SERPINB6 expression. (B–H) Correlation between SERPINB6 expression and the infiltration level of macrophages, neutrophils, eosinophils, aDC, iDC, T cells and NK CD56dim cells.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Expressing

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: SERPINB6 silencing inhibits cell proliferation, migration and invasion in vitro. RT‐qPCR (A) and Immunoblot (B) analysis of SERPINB6 expression in U87 and SNB19 cells after transfection with the sh‐NC, sh‐SERPINB6‐1, or sh‐SERPINB6‐2. GAPDH was used as the loading control. *** p < 0.001 and **** p < 0.0001, one‐way ANOVA. (C, D) Colony formation capacity of sh‐NC, sh‐SERPINB6‐1 and sh‐SERPINB6‐2 groups in U87 and SNB19 cells. * p < 0.05 and ** p < 0.01, one‐way ANOVA. (E–G) EdU assay was applied to compare the cell proliferation ability of sh‐NC, sh‐SERPINB6‐1 and sh‐SERPINB6‐2 groups in U87 and SNB19 cells. ** p < 0.01 and *** p < 0.001, one‐way ANOVA. (H, I) Effect of SERPINB6 on cell invasion by the matrigel transwell assay. * p < 0.05 and ** p < 0.01, one‐way ANOVA. (J, K) Effect of SERPINB6 on cell migration assessed by wound healing assay in 36 h. * p < 0.05 and ** p < 0.01, one‐way ANOVA.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Migration, In Vitro, Quantitative RT-PCR, Western Blot, Expressing, Transfection, Control, EdU Assay, Transwell Assay, Wound Healing Assay

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: SERPINB6 overexpression promotes cell proliferation, migration and invasion in vitro. RT‐qPCR (A) and Immunoblot (B) analysis of SERPINB6 expression in U87 and SNB19 cells after transfection with the OE‐NC or OE‐SERPINB6. GAPDH was used as the loading control. *** p < 0.001 and **** p < 0.0001, Student's t ‐test. (C, D) Colony formation capacity of OE‐NC and OE‐SERPINB6 groups in U87 and SNB19 cells. *** p < 0.001, Student's t ‐test. (E, F) EdU assay was applied to compare the cell proliferation ability of OE‐NC and OE‐SERPINB6 groups in U87 and SNB19 cells. **** p < 0.0001, Student's t ‐test. (G, H) Effect of SERPINB6 on cell invasion by the matrigel transwell assay. *** p < 0.001, Student's t ‐test. (I, J) Effect of SERPINB6 on cell migration assessed by wound healing assay in 36 h. * p < 0.05 and ** p < 0.01, Student's t ‐test.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Over Expression, Migration, In Vitro, Quantitative RT-PCR, Western Blot, Expressing, Transfection, Control, EdU Assay, Transwell Assay, Wound Healing Assay

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: SERPINB6 promotes glioma growth in vivo. (A) Tumorigenicity assays were performed in nude mice following subcutaneous inoculation of SNB19 cells transfected with sh‐NC, sh‐SERPINB6‐1, or sh‐SERPINB6‐2. Tumour (B) volume and (C) weight were measured in the sh‐NC, sh‐SERPINB6‐1 and sh‐SERPINB6‐2 groups. *** p < 0.001, two‐way ANOVA; **** p < 0.0001, one‐way ANOVA. (D) Tumorigenicity assays were performed in nude mice after subcutaneous inoculation of SNB19 cells transfected with OE‐NC or OE‐SERPINB6. Tumour (E) volume and (F) weight were measured in the OE‐NC and OE‐SERPINB6 groups. **** p < 0.0001, two‐way ANOVA; *** p < 0.001, Student's t ‐test. (G) H&E staining and IHC staining of Ki67 and Bax in sh‐NC, sh‐SERPINB6‐1, sh‐SERPINB6‐2, OE‐NC and OE‐SERPINB6 groups. (H, I) Relative expression of Ki67 and Bax in H&E staining, respectively. * p < 0.05, ** p < 0.01, **** p < 0.0001.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: In Vivo, Transfection, Staining, Immunohistochemistry, Expressing

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: Functional enrichment analysis of the differentially expressed genes (DEGs) based on the SERPINB6 expression levels in glioma. (A) The volcano plots show the DEGs in the glioma patients with high‐ and low‐SERPINB6 expression. (B–I) Gene Set Enrichment Analysis (GSEA) of the altered signalling pathways in the glioma tissues based on the SERPINB6‐associated DEGs between the high‐ and low‐SERPINB6 expression groups in glioma.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Functional Assay, Expressing

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: SERPINB6 promotes EMT and PI3K/AKT/mTOR signalling pathway. (A–H) Immunoblot analysis of E‐cadherin, N‐cadherin and Vimentin in U87 and SNB19 cells transfected with sh‐NC, sh‐SERPINB6‐1, sh‐SERPINB6‐2, OE‐NC and OE‐SERPINB6. GAPDH was used as loading control. ** p < 0.01, *** p < 0.001 and **** p < 0.0001, one‐way ANOVA; Student's t ‐test. (I–P) Immunoblot analysis of p‐PI3K, PI3K, p‐AKT, AKT, p‐mTOR and mTOR in U87 and SNB19 cells transfected with sh‐NC, sh‐SERPINB6‐1, sh‐SERPINB6‐2, OE‐NC and OE‐SERPINB6. GAPDH was used as loading control. * p < 0.05, ** p < 0.01 and *** p < 0.001, one‐way ANOVA; Student's t ‐test.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Western Blot, Transfection, Control

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: Inhibiting PI3K/AKT/mTOR signalling retards proliferation, invasion and migration of glioma cells induced by SERPINB6 overexpression. (A, B) Colony formation capacity of OE‐NC, OE‐SERPINB6 and OE‐SERPINB6 combined with Wortmannin groups in U87 and SNB19 cells. ** p < 0.01, one‐way ANOVA. (C–E) EdU assay was applied to compare the cell proliferation ability of OE‐NC, OE‐SERPINB6 and OE‐SERPINB6 combined with Wortmannin groups in U87 and SNB19 cells. ** p < 0.01 and *** p < 0.001, one‐way ANOVA. (F, G) Transwell assay assessed the cell invasion capacity of OE‐NC, OE‐SERPINB6 and OE‐SERPINB6 combined with Wortmannin groups in U87 and SNB19 cells. ** p < 0.01, *** p < 0.001 and **** p < 0.0001, one‐way ANOVA. (H–J) Wound healing assay assessed the cell migration capacity of OE‐NC, OE‐SERPINB6 and OE‐SERPINB6 combined with Wortmannin groups in U87 and SNB19 cells. *** p < 0.001 and **** p < 0.0001, one‐way ANOVA.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Migration, Over Expression, EdU Assay, Transwell Assay, Wound Healing Assay

Journal: Journal of Cellular and Molecular Medicine

Article Title: SERPINB6 Promotes Epithelial‐Mesenchymal Transition via PI3K / AKT / mTOR Signalling Pathway in Glioma

doi: 10.1111/jcmm.70711

Figure Lengend Snippet: Inhibiting PI3K/AKT/mTOR signalling impairs the EMT process of glioma cells induced by SERPINB6 overexpression. (A–E) Immunoblot analysis of E‐cadherin, N‐cadherin, Vimentin, p‐PI3K, PI3K, p‐AKT, AKT, p‐mTOR and mTOR of OE‐NC, OE‐SERPINB6 and OE‐SERPINB6 combined with Wortmannin groups in U87 and SNB19 cells. GAPDH was used as loading control. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

Article Snippet: The primary antibodies, including those against SERPINB6 (1:1200, Proteintech, 14962‐1‐AP), GAPDH (1:1800, Proteintech, 60004‐1‐Ig), E‐cadherin (1:1200, Proteintech, 20874‐1‐AP), N‐cadherin (1:800, Abcam, ab76011), Vimentin (1:1200, CST, 5741), p‐PI3K (1:800, Abcam, ab302958), PI3K (1:1200, CST, 4249), p‐AKT (1:800, CST, 9271), AKT (1:1200, CST, 4060), p‐mTOR (1:800, CST, 5536) and mTOR (1:1200, CST, 2983).

Techniques: Over Expression, Western Blot, Control

Journal: European Journal of Clinical Pharmacology

Article Title: Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile

doi: 10.1007/s00228-011-1205-2

Figure Lengend Snippet: Pharmacodynamic parameters after the administration of dabigatran etexilate 220 mg, with and without enoxaparin ( n = 23) a

Article Snippet: The dTT was measured using the HEMOCLOT thrombin inhibitor assay (HYPHEN BioMed, Neuville sur Oise, France) according to the manufacturer’s instructions.

Techniques: